Huntingtons Disease Treatment Market
SHARE
PUBLISHED: 2023 ID: SMRC22649
SHARE

Huntingtons Disease Treatment Market Forecasts to 2028 - Global Analysis By Treatment (Disease-modifying therapies and Symptomatic treatment), Drug, End User and By Geography

4.4 (82 reviews)
4.4 (82 reviews)
Published: 2023 ID: SMRC22649

This report covers the impact of COVID-19 on this global market
Loading...

Years Covered

2020-2028

Estimated Year Value (2022)

US $8.5 BN

Projected Year Value (2028)

US $18.7 BN

CAGR (2022 - 2028)

14.1%

Regions Covered

North America, Europe, Asia Pacific, South America, and Middle East & Africa

Countries Covered

US, Canada, Mexico, Germany, UK, Italy, France, Spain, Japan, China, India, Australia, New Zealand, South Korea, Rest of Asia Pacific, South America, Argentina, Brazil, Chile, Middle East & Africa, Saudi Arabia, UAE, Qatar, and South Africa

Largest Market

Asia Pacific

Highest Growing Market

North America


According to Stratistics MRC, the Global Huntington’s Disease Treatment Market is accounted for $8.5 billion in 2022 and is expected to reach $18.7 billion by 2028 growing at a CAGR of 14.1% during the forecast period. Huntington’s disease is a rare inherited disease that causes progressive breakdown of nerve cells in the brain, mainly affecting physical movements, emotions and cognitive abilities. It is a condition in which the nerve cells of the brain malfunction and create clumps of a protein called neurofibrillary tangles that affect movement, thinking, reasoning, moods, and more. It can cause uncontrolled movements or muscle twitches (chorea), changes in speech patterns, depression, anxiety, and personality changes.

According to the Huntington’s disease Society of America (HDSA), there were approximately 41,000 symptomatic Americans in 2021, with over 200,000 individuals at risk of inheriting the disease.



Market Dynamics:

Driver:

The rising incidence of Huntington's disease

The rising incidence of Huntington's disease across the globe is one of the primary factors driving the market growth. The procedure is frequently used to stop uncontrollable jerking and writhing motion, which enhances quality of life. In addition, clinical trials, strong drug type pipeline and growing adoption of improved medical treatments and therapies are expected to fuel the market growth.

Restraint:

Lack of approved drugs and stringent regulatory policies

Currently, there are only two drugs approved for the treatment of chorea associated with this condition and these drugs can only manage or control the symptoms but cannot cure the disease. Companies across the globe need to clear strict regulatory hurdles for the approval of drugs. Such regulatory limits may impact market participants' preferences, resulting in slower market growth during the projection period.

Opportunity:

Growing research and development activities

There is a vast area of research and development for Huntington's disease treatment approaches because there is no effective treatment or medication. This is expected to significantly boost market growth during the forecast period. Moreover, the promising government initiatives that promote the development of new drugs are estimated to be another factor supporting the market growth.

Threat:

Limited availability of drugs

The number of licensed pharmaceuticals is limited due to tight policies and restrictions. It is anticipated that the market's expansion will be constrained by the lack of knowledge about this illness in many regions of the world. Many medications have failed to show efficacy or have been linked to significant toxicity, which has presented significant challenges for the discovery of drugs to treat the disease. This is expected to hamper the market growth.

Covid-19 Impact

The COVID-19 outbreak is projected to have a detrimental effect on the size of the market for treating Huntington's disease. To accommodate more patients with COVID-19, a sizable number of clinics and hospitals around the world underwent restructuring. Because of the sharp increase in patients, non-essential operations could be delayed. Production and delivery of supplies for healthcare were halted as a result of the lockdown. Lack of access to healthcare, a staffing deficit in the medical field, and an increase in COVID-19-related hospitalisation are some additional variables that have an impact on the market.

The disease-modifying therapies segment is expected to be the largest during the forecast period

The disease-modifying therapies segment is estimated to have a lucrative growth, due to an increase in disease-modifying therapy R&D. They can be administered intravenously or orally to lessen current symptoms or slow their progression. Disease-modifying therapies can help with problems like psychological illnesses and depression linked to this condition, but they have not been found to change patient mortality rates.

The antidepressants segment is expected to have the highest CAGR during the forecast period

The antidepressants segment is anticipated to witness the fastest CAGR growth during the forecast period, due to they are intended to restore the mental stability. Antidepressants are prescription medications that can help with symptoms of clinical depression, dysthymia, social anxiety, anxiety, and other conditions. Treatment with antidepressants focuses primarily on reducing the symptoms of severe depression. These are driving the segment growth.

Region with Largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to the comparatively lower prevalence rate of this condition amongst the population. However, increasing awareness among the patient population toward available treatment along with improving reimbursement policies in these regions during the forecast period will contribute to their growth prospects.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, owing to the increasing product penetration. A high level of public awareness about the condition, as well as growing support from numerous public and private organisations through research funding, to expedite the study of this disease. As governments take more initiatives to improve the health status of the populations, the market in the region is expected to grow.



Key players in the market

Some of the key players profiled in the Huntington’s Disease Treatment Market include Novartis AG, Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Sun Pharmaceutical Industries, Inc., Lupin, Hetero, Hikma Pharmaceuticals PLC, Bausch Health Companies Inc., Alterity Therapeutics, H. Lundbeck A/S, Neurocrine Biosciences, Inc., Annexon Biosciences, PTC Therapeutics, Prilenia Therapeutics, Amneal Pharmaceuticals LLC., SOM BIOTECH and Vertex Pharmaceuticals Incorporated.

Key Developments:

In December 2021, Novartis AG received Fast Track designation for Branaplam from the FDA for Huntington’s disease treatment. Branaplam is an mRNA splicing modulator that targets the HTT protein responsible for causing the degeneration of nerve cells leading to Huntington’s disease.

In October 2021, Teva Pharmaceutical Industries Ltd. received marketing approval for the treatment of chorea associated with Huntington’s disease treatment and for the treatment of tardive dyskinesia in Brazil.

Treatments Covered:
• Disease-modifying therapies
• Symptomatic treatment

Drugs Covered:
• Antidepressants
• Antipsychotic Drugs
• Tranquilizers
• Tetrabenazine
• Other Drugs

End Users Covered:
• Clinics
• Hospital
• Retail Pharmacies
• Online Pharmacies
• Other End Users

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions

3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 End User Analysis
3.7 Emerging Markets
3.8 Impact of Covid-19

4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Huntington’s Disease Treatment Market, By Treatment
5.1 Introduction
5.2 Disease-modifying therapies
5.3 Symptomatic treatment

6 Global Huntington’s Disease Treatment Market, By Drug
6.1 Introduction
6.2 Antidepressants
6.3 Antipsychotic Drugs
6.4 Tranquilizers
6.5 Tetrabenazine
6.6 Other Drugs

7 Global Huntington’s Disease Treatment Market, By End User
7.1 Introduction
7.2 Clinics
7.3 Hospital
7.4 Retail Pharmacies
7.5 Online Pharmacies
7.6 Other End Users

8 Global Huntington’s Disease Treatment Market, By Geography
8.1 Introduction
8.2 North America
8.2.1 US
8.2.2 Canada
8.2.3 Mexico
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 Italy
8.3.4 France
8.3.5 Spain
8.3.6 Rest of Europe
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 New Zealand
8.4.6 South Korea
8.4.7 Rest of Asia Pacific
8.5 South America
8.5.1 Argentina
8.5.2 Brazil
8.5.3 Chile
8.5.4 Rest of South America
8.6 Middle East & Africa
8.6.1 Saudi Arabia
8.6.2 UAE
8.6.3 Qatar
8.6.4 South Africa
8.6.5 Rest of Middle East & Africa

9 Key Developments
9.1 Agreements, Partnerships, Collaborations and Joint Ventures
9.2 Acquisitions & Mergers
9.3 New Product Launch
9.4 Expansions
9.5 Other Key Strategies

10 Company Profiling
10.1 Novartis AG
10.2 Teva Pharmaceutical Industries Ltd.
10.3 Dr. Reddy’s Laboratories Ltd.
10.4 Sun Pharmaceutical Industries, Inc.
10.5 Lupin
10.6 Hetero
10.7 Hikma Pharmaceuticals PLC
10.8 Bausch Health Companies Inc.
10.9 Alterity Therapeutics
10.10 H. Lundbeck A/S
10.11 Neurocrine Biosciences, Inc.
10.12 Annexon Biosciences
10.13 PTC Therapeutics
10.14 Prilenia Therapeutics
10.15 Amneal Pharmaceuticals LLC.
10.16 SOM BIOTECH
10.17 Vertex Pharmaceuticals Incorporated

List of Tables
1 Global Huntington’s Disease Treatment Market Outlook, By Region (2020-2028) ($MN)
2 Global Huntington’s Disease Treatment Market Outlook, By Treatment (2020-2028) ($MN)
3 Global Huntington’s Disease Treatment Market Outlook, By Disease-modifying therapies (2020-2028) ($MN)
4 Global Huntington’s Disease Treatment Market Outlook, By Symptomatic treatment (2020-2028) ($MN)
5 Global Huntington’s Disease Treatment Market Outlook, By Drug (2020-2028) ($MN)
6 Global Huntington’s Disease Treatment Market Outlook, By Antidepressants (2020-2028) ($MN)
7 Global Huntington’s Disease Treatment Market Outlook, By Antipsychotic Drugs (2020-2028) ($MN)
8 Global Huntington’s Disease Treatment Market Outlook, By Tranquilizers (2020-2028) ($MN)
9 Global Huntington’s Disease Treatment Market Outlook, By Tetrabenazine (2020-2028) ($MN)
10 Global Huntington’s Disease Treatment Market Outlook, By Other Drugs (2020-2028) ($MN)
11 Global Huntington’s Disease Treatment Market Outlook, By End User (2020-2028) ($MN)
12 Global Huntington’s Disease Treatment Market Outlook, By Clinics (2020-2028) ($MN)
13 Global Huntington’s Disease Treatment Market Outlook, By Hospital (2020-2028) ($MN)
14 Global Huntington’s Disease Treatment Market Outlook, By Retail Pharmacies (2020-2028) ($MN)
15 Global Huntington’s Disease Treatment Market Outlook, By Online Pharmacies (2020-2028) ($MN)
16 Global Huntington’s Disease Treatment Market Outlook, By Other End Users (2020-2028) ($MN)
17 North America Huntington’s Disease Treatment Market Outlook, By Country (2020-2028) ($MN)
18 North America Huntington’s Disease Treatment Market Outlook, By Treatment (2020-2028) ($MN)
19 North America Huntington’s Disease Treatment Market Outlook, By Disease-modifying therapies (2020-2028) ($MN)
20 North America Huntington’s Disease Treatment Market Outlook, By Symptomatic treatment (2020-2028) ($MN)
21 North America Huntington’s Disease Treatment Market Outlook, By Drug (2020-2028) ($MN)
22 North America Huntington’s Disease Treatment Market Outlook, By Antidepressants (2020-2028) ($MN)
23 North America Huntington’s Disease Treatment Market Outlook, By Antipsychotic Drugs (2020-2028) ($MN)
24 North America Huntington’s Disease Treatment Market Outlook, By Tranquilizers (2020-2028) ($MN)
25 North America Huntington’s Disease Treatment Market Outlook, By Tetrabenazine (2020-2028) ($MN)
26 North America Huntington’s Disease Treatment Market Outlook, By Other Drugs (2020-2028) ($MN)
27 North America Huntington’s Disease Treatment Market Outlook, By End User (2020-2028) ($MN)
28 North America Huntington’s Disease Treatment Market Outlook, By Clinics (2020-2028) ($MN)
29 North America Huntington’s Disease Treatment Market Outlook, By Hospital (2020-2028) ($MN)
30 North America Huntington’s Disease Treatment Market Outlook, By Retail Pharmacies (2020-2028) ($MN)
31 North America Huntington’s Disease Treatment Market Outlook, By Online Pharmacies (2020-2028) ($MN)
32 North America Huntington’s Disease Treatment Market Outlook, By Other End Users (2020-2028) ($MN)
33 Europe Huntington’s Disease Treatment Market Outlook, By Country (2020-2028) ($MN)
34 Europe Huntington’s Disease Treatment Market Outlook, By Treatment (2020-2028) ($MN)
35 Europe Huntington’s Disease Treatment Market Outlook, By Disease-modifying therapies (2020-2028) ($MN)
36 Europe Huntington’s Disease Treatment Market Outlook, By Symptomatic treatment (2020-2028) ($MN)
37 Europe Huntington’s Disease Treatment Market Outlook, By Drug (2020-2028) ($MN)
38 Europe Huntington’s Disease Treatment Market Outlook, By Antidepressants (2020-2028) ($MN)
39 Europe Huntington’s Disease Treatment Market Outlook, By Antipsychotic Drugs (2020-2028) ($MN)
40 Europe Huntington’s Disease Treatment Market Outlook, By Tranquilizers (2020-2028) ($MN)
41 Europe Huntington’s Disease Treatment Market Outlook, By Tetrabenazine (2020-2028) ($MN)
42 Europe Huntington’s Disease Treatment Market Outlook, By Other Drugs (2020-2028) ($MN)
43 Europe Huntington’s Disease Treatment Market Outlook, By End User (2020-2028) ($MN)
44 Europe Huntington’s Disease Treatment Market Outlook, By Clinics (2020-2028) ($MN)
45 Europe Huntington’s Disease Treatment Market Outlook, By Hospital (2020-2028) ($MN)
46 Europe Huntington’s Disease Treatment Market Outlook, By Retail Pharmacies (2020-2028) ($MN)
47 Europe Huntington’s Disease Treatment Market Outlook, By Online Pharmacies (2020-2028) ($MN)
48 Europe Huntington’s Disease Treatment Market Outlook, By Other End Users (2020-2028) ($MN)
49 Asia Pacifiic Huntington’s Disease Treatment Market Outlook, By Country (2020-2028) ($MN)
50 Asia Pacifiic Huntington’s Disease Treatment Market Outlook, By Treatment (2020-2028) ($MN)
51 Asia Pacifiic Huntington’s Disease Treatment Market Outlook, By Disease-modifying therapies (2020-2028) ($MN)
52 Asia Pacifiic Huntington’s Disease Treatment Market Outlook, By Symptomatic treatment (2020-2028) ($MN)
53 Asia Pacifiic Huntington’s Disease Treatment Market Outlook, By Drug (2020-2028) ($MN)
54 Asia Pacifiic Huntington’s Disease Treatment Market Outlook, By Antidepressants (2020-2028) ($MN)
55 Asia Pacifiic Huntington’s Disease Treatment Market Outlook, By Antipsychotic Drugs (2020-2028) ($MN)
56 Asia Pacifiic Huntington’s Disease Treatment Market Outlook, By Tranquilizers (2020-2028) ($MN)
57 Asia Pacifiic Huntington’s Disease Treatment Market Outlook, By Tetrabenazine (2020-2028) ($MN)
58 Asia Pacifiic Huntington’s Disease Treatment Market Outlook, By Other Drugs (2020-2028) ($MN)
59 Asia Pacifiic Huntington’s Disease Treatment Market Outlook, By End User (2020-2028) ($MN)
60 Asia Pacifiic Huntington’s Disease Treatment Market Outlook, By Clinics (2020-2028) ($MN)
61 Asia Pacifiic Huntington’s Disease Treatment Market Outlook, By Hospital (2020-2028) ($MN)
62 Asia Pacifiic Huntington’s Disease Treatment Market Outlook, By Retail Pharmacies (2020-2028) ($MN)
63 Asia Pacifiic Huntington’s Disease Treatment Market Outlook, By Online Pharmacies (2020-2028) ($MN)
64 Asia Pacifiic Huntington’s Disease Treatment Market Outlook, By Other End Users (2020-2028) ($MN)
65 South America Huntington’s Disease Treatment Market Outlook, By Country (2020-2028) ($MN)
66 South America Huntington’s Disease Treatment Market Outlook, By Treatment (2020-2028) ($MN)
67 South America Huntington’s Disease Treatment Market Outlook, By Disease-modifying therapies (2020-2028) ($MN)
68 South America Huntington’s Disease Treatment Market Outlook, By Symptomatic treatment (2020-2028) ($MN)
69 South America Huntington’s Disease Treatment Market Outlook, By Drug (2020-2028) ($MN)
70 South America Huntington’s Disease Treatment Market Outlook, By Antidepressants (2020-2028) ($MN)
71 South America Huntington’s Disease Treatment Market Outlook, By Antipsychotic Drugs (2020-2028) ($MN)
72 South America Huntington’s Disease Treatment Market Outlook, By Tranquilizers (2020-2028) ($MN)
73 South America Huntington’s Disease Treatment Market Outlook, By Tetrabenazine (2020-2028) ($MN)
74 South America Huntington’s Disease Treatment Market Outlook, By Other Drugs (2020-2028) ($MN)
75 South America Huntington’s Disease Treatment Market Outlook, By End User (2020-2028) ($MN)
76 South America Huntington’s Disease Treatment Market Outlook, By Clinics (2020-2028) ($MN)
77 South America Huntington’s Disease Treatment Market Outlook, By Hospital (2020-2028) ($MN)
78 South America Huntington’s Disease Treatment Market Outlook, By Retail Pharmacies (2020-2028) ($MN)
79 South America Huntington’s Disease Treatment Market Outlook, By Online Pharmacies (2020-2028) ($MN)
80 South America Huntington’s Disease Treatment Market Outlook, By Other End Users (2020-2028) ($MN)
81 Middle East & Africa Huntington’s Disease Treatment Market Outlook, By Country (2020-2028) ($MN)
82 Middle East & Africa Huntington’s Disease Treatment Market Outlook, By Treatment (2020-2028) ($MN)
83 Middle East & Africa Huntington’s Disease Treatment Market Outlook, By Disease-modifying therapies (2020-2028) ($MN)
84 Middle East & Africa Huntington’s Disease Treatment Market Outlook, By Symptomatic treatment (2020-2028) ($MN)
85 Middle East & Africa Huntington’s Disease Treatment Market Outlook, By Drug (2020-2028) ($MN)
86 Middle East & Africa Huntington’s Disease Treatment Market Outlook, By Antidepressants (2020-2028) ($MN)
87 Middle East & Africa Huntington’s Disease Treatment Market Outlook, By Antipsychotic Drugs (2020-2028) ($MN)
88 Middle East & Africa Huntington’s Disease Treatment Market Outlook, By Tranquilizers (2020-2028) ($MN)
89 Middle East & Africa Huntington’s Disease Treatment Market Outlook, By Tetrabenazine (2020-2028) ($MN)
90 Middle East & Africa Huntington’s Disease Treatment Market Outlook, By Other Drugs (2020-2028) ($MN)
91 Middle East & Africa Huntington’s Disease Treatment Market Outlook, By End User (2020-2028) ($MN)
92 Middle East & Africa Huntington’s Disease Treatment Market Outlook, By Clinics (2020-2028) ($MN)
93 Middle East & Africa Huntington’s Disease Treatment Market Outlook, By Hospital (2020-2028) ($MN)
94 Middle East & Africa Huntington’s Disease Treatment Market Outlook, By Retail Pharmacies (2020-2028) ($MN)
95 Middle East & Africa Huntington’s Disease Treatment Market Outlook, By Online Pharmacies (2020-2028) ($MN)
96 Middle East & Africa Huntington’s Disease Treatment Market Outlook, By Other End Users (2020-2028) ($MN)

Frequently Asked Questions

In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929

Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.

Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.

All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929

We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.

We have 3 different licensing options available in electronic format.

  • Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
  • 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
  • Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.

All our reports are typically be emailed to you as an attachment.

To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.

We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.

Request Customization

We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.

Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.

WHY CHOOSE US ?

Assured Quality

Assured Quality

Best in class reports with high standard of research integrity

24X7 Research Support

24X7 Research Support

Continuous support to ensure the best customer experience.

Free Customization

Free Customization

Adding more values to your product of interest.

Safe and Secure Access

Safe & Secure Access

Providing a secured environment for all online transactions.

Trusted by 600+ Brands

Trusted by 600+ Brands

Serving the most reputed brands across the world.

Testimonials